Biogen stock forecast
Biogen's weighted scenario is $251.74 by October 2029. Biogen's outcome hinges on newer and acquired products replacing mature sales while debt is repaid.
Where could Biogen's shares be by October 2029?
The forecast sees Biogen producing a small loss before dividends in the first two years, followed by a modest gain in the third. At today’s $233.48, the weighted prices are $214.94 in October 2027, $232.17 in October 2028 and $251.74 in October 2029. Including dividends, those outcomes equal returns of negative 8%, negative 1% and positive 8%.
The range is much wider than the weighted result suggests. By October 2029, the bear case reaches $94.00 and the bull case reaches $461.86, against today’s price. The final probabilities are 28% bear, 55% base and 17% bull.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 28 % | 138.15 (-41 %) | 114.20 (-51 %) | 94.00 (-60 %) |
| Base | 55 % | 228.85 (-2 %) | 247.53 (+6 %) | 267.09 (+14 %) |
| Bull | 17 % | 296.42 (+27 %) | 376.80 (+61 %) | 461.86 (+98 %) |
| Weighted | 100 % | 214.94 (-8 %) | 232.17 (-1 %) | 251.74 (+8 %) |
What has to go right or wrong for Biogen?
The base assumes newer and acquired products partly replace mature-product erosion. SKYCLARYS grew 29% in the second quarter, and QALSODY grew 59%. ZURZUVAE also grew 53%. The bear case assumes those gains fail to offset a 49.9% fall in Tecfidera revenue. The bull case assumes broad uptake, successful Apellis integration and at least $250 million of annualized synergies. Net debt of $6,805.3 million limits how quickly those savings can reach shareholders.
How much cash does Biogen really make?
Biogen defines free cash flow as operating cash flow less capital spending. That produced $2,050.8 million in 2025, down 24.7%. Subtracting $290.8 million of stock pay gives an owner-oriented “real free cash flow” of $1,760.0 million. Stock compensation is not another cash payment, but it gives employees an ownership claim and therefore has an economic cost.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 2,204.6 | 2,875.5 | 1,547.2 | 1,384.3 | 3,639.9 |
| − Capital spending | 153.8 | 153.7 | 277.0 | 240.3 | 258.1 |
| = Free cash flow | 2,050.8 | 2,721.8 | 1,270.2 | 1,144.0 | 3,381.8 |
| − Stock pay | 290.8 | 291.2 | 264.2 | 254.1 | 238.6 |
| = Real free cash flow | 1,760.0 | 2,430.6 | 1,006.0 | 889.9 | 3,143.2 |
What this means. Real free cash flow is lower because paying employees with shares costs no cash but gives away part of the company.
What does an investor pay for Biogen today?
On October 19, 2026, the stock price was $233.48. At a forward P/E of 14.2x, that price implies earnings of about $16.44 per share. The trailing P/E is 41.3x. That implies trailing earnings of about $5.65 per share. The gap is too large to treat as simple operating growth; the accounting bases must differ.
| Today (Oct 19, 2026) | |
|---|---|
| Share price | 233.48 |
| P/E, last 12 months (calculated) | 41.3x |
| P/E, next 12 months (calculated) | 14.2x |
| Free cash flow yield (calculated) | 5.9% |
| Real free cash flow yield (calculated) | 5.1% |
What this means. The much lower price-to-profit number for the next year means analysts expect the company's profit to rise sharply.